Chugai Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Chugai Pharmaceutical has been growing earnings at an average annual rate of 20.7%, while the Pharmaceuticals industry saw earnings growing at 3.6% annually. Revenues have been growing at an average rate of 15.1% per year. Chugai Pharmaceutical's return on equity is 19.9%, and it has net margins of 31.5%.
Key information
20.7%
Earnings growth rate
20.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 15.1% |
| Return on equity | 19.9% |
| Net Margin | 31.5% |
| Next Earnings Update | 25 Jul 2024 |
Revenue & Expenses BreakdownBeta
How Chugai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,036,076 | 326,373 | 114,150 | 173,356 |
| 31 Dec 23 | 1,111,367 | 325,472 | 112,580 | 174,868 |
| 30 Sep 23 | 1,276,051 | 336,745 | 112,702 | 178,244 |
| 30 Jun 23 | 1,243,437 | 326,969 | 107,753 | 169,379 |
| 31 Mar 23 | 1,211,632 | 316,154 | 96,519 | 158,627 |
| 31 Dec 22 | 1,259,946 | 374,429 | 100,760 | 149,626 |
| 30 Sep 22 | 1,143,716 | 370,791 | 104,720 | 142,201 |
| 30 Jun 22 | 1,205,696 | 389,011 | 106,839 | 141,695 |
| 31 Mar 22 | 1,191,496 | 387,359 | 107,887 | 141,438 |
| 31 Dec 21 | 999,759 | 302,995 | 102,416 | 137,299 |
| 30 Sep 21 | 887,919 | 256,462 | 98,992 | 132,324 |
| 30 Jun 21 | 809,055 | 230,577 | 96,489 | 126,265 |
| 31 Mar 21 | 776,339 | 210,611 | 94,546 | 121,477 |
| 31 Dec 20 | 786,946 | 214,733 | 94,401 | 117,850 |
| 30 Sep 20 | 753,853 | 202,590 | 95,497 | 116,049 |
| 30 Jun 20 | 734,019 | 190,599 | 96,919 | 110,994 |
| 31 Mar 20 | 711,320 | 174,062 | 102,068 | 108,903 |
| 31 Dec 19 | 686,184 | 157,560 | 101,574 | 107,942 |
| 30 Sep 19 | 662,198 | 139,543 | 99,844 | 105,231 |
| 30 Jun 19 | 614,949 | 113,070 | 97,895 | 102,491 |
| 31 Mar 19 | 586,648 | 99,631 | 92,379 | 99,289 |
| 31 Dec 18 | 579,787 | 92,488 | 93,416 | 99,202 |
| 30 Sep 18 | 572,994 | 85,857 | 91,553 | 98,150 |
| 30 Jun 18 | 566,548 | 85,285 | 89,710 | 96,639 |
| 31 Mar 18 | 556,159 | 82,101 | 89,631 | 98,744 |
| 31 Dec 17 | 534,199 | 72,713 | 88,147 | 92,947 |
| 30 Sep 17 | 517,908 | 67,704 | 82,411 | 90,427 |
| 30 Jun 17 | 497,023 | 58,143 | 82,465 | 89,728 |
| 31 Mar 17 | 497,354 | 57,592 | 81,248 | 85,000 |
| 31 Dec 16 | 491,780 | 53,592 | 81,941 | 85,011 |
| 30 Sep 16 | 492,584 | 56,562 | 85,481 | 83,366 |
| 30 Jun 16 | 506,192 | 62,537 | 86,313 | 84,761 |
| 31 Mar 16 | 501,649 | 61,043 | 87,772 | 84,111 |
| 31 Dec 15 | 498,839 | 61,125 | 88,018 | 83,799 |
| 30 Sep 15 | 495,455 | 58,897 | 85,492 | 85,815 |
| 30 Jun 15 | 479,265 | 52,220 | 86,648 | 83,082 |
| 31 Mar 15 | 454,147 | 46,786 | 86,134 | 81,284 |
| 31 Dec 14 | 461,109 | 50,980 | 85,655 | 80,625 |
| 30 Sep 14 | 450,545 | 52,461 | 84,305 | 75,413 |
| 30 Jun 14 | 444,658 | 55,044 | 83,535 | 76,124 |
| 31 Mar 14 | 457,281 | 60,774 | 84,336 | 76,087 |
| 31 Dec 13 | 423,652 | 50,895 | 83,566 | 72,706 |
| 30 Sep 13 | 422,345 | 56,528 | 86,690 | 69,435 |
| 30 Jun 13 | 406,973 | 52,064 | 88,710 | 63,728 |
Quality Earnings: 4519 has high quality earnings.
Growing Profit Margin: 4519's current net profit margins (31.5%) are higher than last year (26.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4519's earnings have grown significantly by 20.7% per year over the past 5 years.
Accelerating Growth: 4519's earnings growth over the past year (3.2%) is below its 5-year average (20.7% per year).
Earnings vs Industry: 4519 earnings growth over the past year (3.2%) exceeded the Pharmaceuticals industry 0.6%.
Return on Equity
High ROE: 4519's Return on Equity (19.9%) is considered low.